Lung Cancer

Latest News

February 23rd 2017

FDA Grants Ceritinib Priority Review in Frontline ALK+ NSCLC

The FDA has granted a priority review to ceritinib as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer.

February 21st 2017

Final Thoughts on Squamous NSCLC Research

February 21st 2017

EGFR-Targeted Therapy for Squamous NCSLC

February 21st 2017

Further Sequencing in Squamous NSCLC

February 21st 2017

Choosing Second-Line Therapy for Squamous NSCLC

Latest Videos

Negative I/O Trials: CheckMate331 and CheckMate 451

Checkpoint Inhibitors in Second and Third-line

SCLC Therapy: First-line Options Prior to Immunotherapy

The Initial Approach to SCLC Treatment

Small Cell Lung Cancer: Future Directions in Care

$I-O Strategies in Relapsed/Refractory SCLC$

I-O Strategies in Relapsed/Refractory SCLC

Frontline I-O Strategies in SCLC: Practical Implications

Results From the CASPIAN Trial in SCLC

Small Cell Lung Cancer: Interpreting Data From IMpower133

Current Frontline Management of Small Cell Lung Cancer

CME Content

Virtual Event

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Video

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Virtual Event

Arkansas Association of Cancer Professionals

1 Session is Available!

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Video

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Virtual Event

Tennessee Oncology Practice Society

1 Session is Available!

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

Video

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Virtual Event

Kansas Society of Clinical Oncology

2 Sessions are Available!

In-Person + Virtual Event

Satellite Symposia at the Annual Radiation Oncology Meeting

September 27-28, 2026

Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Virtual Event

Texas Society of Clinical Oncology

1 Session is Available!

Virtual Event

North Carolina Oncology Association

2 Sessions are Available!

Virtual Event

Louisiana Oncology Society

2 Sessions are Available!

Virtual Event

Washington State Medical Oncology Society

2 Sessions are Available!

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Video

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; Anitha Varghese, MSN, APRN, AGPCNP-C

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Video

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Video

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Video

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

More News

Maintenance Therapy for Squamous NSCLC

February 21st 2017

Chemotherapy for Newly Diagnosed Squamous NSCLC

February 21st 2017

Promising Immunotherapy Trials in Squamous NSCLC

February 21st 2017

Pseudoprogression on Immunotherapy in Squamous NSCLC

February 21st 2017

Toxicities Associated with Anti-PD-1 Immunotherapy

February 21st 2017

Pembrolizumab in Newly Diagnosed Squamous NSCLC

February 21st 2017

PD-L1 Testing in Squamous NSCLC

February 21st 2017

EGFR & ALK/ROS1 Testing in Squamous NSCLC

February 21st 2017

What to Do After Progression on Immunotherapy and for Non-Driver NSCLC

February 20th 2017

New Data for Checkpoint Inhibitors in NSCLC

February 20th 2017

Upfront Use of Immunotherapy for NCSLC

February 20th 2017

Third-Generation ALK Inhibitors for NSCLC

February 20th 2017

Upfront Use of Next-Generation ALK Inhibitors in NSCLC

February 20th 2017

Upfront Use of Osimertinib in EGFR+ NSCLC

February 20th 2017

Osimertinib for EGFR T790M Resistance Mutations in NSCLC

February 20th 2017

Relapsed or Refractory EGFR+ NSCLC

February 20th 2017

Addition of Bevacizumab to Up-front therapy for EGFR+ NSCLC

February 20th 2017

Molecular Testing for NSCLC in 2017

February 20th 2017

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

ByGina Columbus

February 16th 2017

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

Rovalpituzumab Tesirine Active and Safe in Small Cell Lung Cancer

ByAllie Strickler

February 13th 2017

Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer.

Dr. Levine on Simulation in the Management of EGFR-Mutated Advanced NSCLC

ByStacie Levine, MD

February 10th 2017

Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC

Lung Cancer

Latest News

Latest Videos

Negative I/O Trials: CheckMate331 and CheckMate 451

Checkpoint Inhibitors in Second and Third-line

SCLC Therapy: First-line Options Prior to Immunotherapy

The Initial Approach to SCLC Treatment

Small Cell Lung Cancer: Future Directions in Care

I-O Strategies in Relapsed/Refractory SCLC

Frontline I-O Strategies in SCLC: Practical Implications

Results From the CASPIAN Trial in SCLC

Small Cell Lung Cancer: Interpreting Data From IMpower133

Current Frontline Management of Small Cell Lung Cancer

CME Content

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Optimizing Treatment for Biliary Tract Cancers

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® West

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Tennessee Oncology Practice Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Kansas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

27th Annual International Lung Cancer Congress®

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Texas Society of Clinical Oncology

North Carolina Oncology Association

Louisiana Oncology Society

Washington State Medical Oncology Society

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

More News

Maintenance Therapy for Squamous NSCLC

Chemotherapy for Newly Diagnosed Squamous NSCLC

Promising Immunotherapy Trials in Squamous NSCLC

Pseudoprogression on Immunotherapy in Squamous NSCLC

Toxicities Associated with Anti-PD-1 Immunotherapy

Pembrolizumab in Newly Diagnosed Squamous NSCLC

PD-L1 Testing in Squamous NSCLC

EGFR & ALK/ROS1 Testing in Squamous NSCLC

What to Do After Progression on Immunotherapy and for Non-Driver NSCLC

New Data for Checkpoint Inhibitors in NSCLC

PD-L1 Testing for NSCLC

Upfront Use of Immunotherapy for NCSLC

Third-Generation ALK Inhibitors for NSCLC

Upfront Use of Next-Generation ALK Inhibitors in NSCLC

Progression of ALK+ NSCLC

Upfront Use of Osimertinib in EGFR+ NSCLC